SCHEMBL4709933

SCHEMBL4709933

COC1CCN(C(=O)c2cc3nccc(Cl)c3s2)C1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.43
MET P08581 2/20 0.43
ADORA2A P29274 7/20 0.43
ADORA2B P29275 5/20 0.43
ADORA3 P0DMS8 2/20 0.43
PARP1 P09874 2/20 0.43
PARP2 Q9UGN5 2/20 0.43
FLT1 P17948 1/20 0.42
MAPT P10636 1/20 0.41
PDE7B Q9NP56 3/20 0.40
POLB P06746 1/20 0.39
PROKR1 Q8TCW9 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4709934 1.00 KDR (0.43) KDRMETADORA2AADORA2BADORA3
SCHEMBL5240097 1.00 KDR (0.43) KDRMETADORA2AADORA2BADORA3
SCHEMBL5240306 0.91 PDE4A (0.40) KDRMETADORA2AADORA2BADORA3
SCHEMBL6304606 0.89 VNN1 (0.44) KDRMETADORA2AADORA2BFLT1
SCHEMBL6304406 0.89 VNN1 (0.44) KDRMETADORA2AADORA2BFLT1
SCHEMBL6304405 0.89 VNN1 (0.44) KDRMETADORA2AADORA2BFLT1
SCHEMBL6302431 0.88 KDR (0.42) KDRMETFLT1MAPTPOLB
SCHEMBL6304681 0.88 KDR (0.42) KDRMETFLT1MAPTPOLB
SCHEMBL6302428 0.88 KDR (0.42) KDRMETFLT1MAPTPOLB
SCHEMBL14839965 0.86 MET (0.53) KDRMETMAPTPOLBPROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660504-B1 THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS PFIZER (US) 2008-10-29 EP disclosed
EP-1515975-B1 BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE PFIZER (US) 2007-09-19 EP disclosed
US-7208500-B2 Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents AGOURON PHARMACEUTICALS, INC. (US) 2007-04-24 US disclosed
EP-1660504-A1 THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2006-05-31 EP disclosed
US-7045528-B2 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-16 US disclosed
US-20060079548-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use AGOURON PHARMACEUTICALS, INC. 2006-04-13 US disclosed
US-6995171-B2 Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents AGOURON PHARMACEUTICALS, INC. (US) 2006-02-07 US disclosed
US-6964961-B2 Thiophene derivatives useful as anticancer agents PFIZER INC (US) 2005-11-15 US disclosed
US-20050090509-A1 Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents Agouron Pharmaceuticals,Inc. 2005-04-28 US disclosed
EP-1515975-A1 BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE PFIZER INC. (US) 2005-03-23 EP disclosed
WO-2005021554-A1 THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2005-03-10 WO disclosed
EP-1287001-B1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-29 EP disclosed
US-20040186126-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-23 US disclosed
US-20040171590-A1 Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents AUTRY CHRISTOPHER (US) 2004-09-02 US disclosed
WO-2003106462-A1 BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE PFIZER INC. (US) 2003-12-24 WO disclosed
EP-1287001-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2003-03-05 EP disclosed
WO-2003000194-A2 THIENOPYRIDINE AND THIENOPYRIMIDINE ANTICANCER AGENTS PFIZER INC. (US) 2003-01-03 WO disclosed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US disclosed
WO-2001094353-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171590-A1 Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents TK1, TYMP, DPYD KDR 1886/4885MET 3998/4885ADORA2A 394/4885
US-20050090509-A1 Thienopyridine-phenylacetamides and their derivatives useful as new anti-angiogenic agents CCNA1, PGF, CCNA2 KDR 23/4885MET 1670/4885ADORA2A 474/4885
US-20040186126-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use DPYD, DHFR, TYMP KDR 1885/4885MET 2469/4885ADORA2A 2037/4885
US-20020042409-A1 Thiophene derivatives useful as anticancer agents TP53, RCC1, CCNA1 KDR 3335/4885MET 1920/4885ADORA2A 3116/4885
US-20060079548-A1 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use TPD52L2, DPYD, CCND2 KDR 1802/4885MET 2699/4885ADORA2A 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.